Manufacture two billion doses of COVID-19 vaccine
Deadline passed; outcome being checked
- Announced
- 1 Feb 2021
- Due
- 31 Dec 2021
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we plan to manufacture two billion doses of our COVID-19 vaccine in 2021”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Language weakened: expected → aspirational
- 2 versions
-
Version 1 · original · stated 1 Feb 2021
Deadline 31 Dec 2021 (“in 2021”) · wording expected
-
Version 2 · stated 17 Feb 2021
Deadline 31 Dec 2021 (“by the end of 2021”) · wording aspirational
“Globally, Pfizer and BioNTech aim to manufacture approximately two billion doses in total by the end of 2021”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Manufacture
- Deliverable
- 2 billion doses of COVID-19 vaccine
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you BioNTech SE? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BNTX-022764 · Corrections policy